BVS
Bioventus Inc
13.10$
-2.4%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +12.1% | -4.4% | +16.8% | -8.1% | +10.6% | -19.4% | +19.2% | -6.1% | +13.9% | -16.3% | +16.0% | – | |
| – | +17.1% | -16.4% | +15.8% | -4.6% | +12.3% | -16.8% | +10.8% | -2.5% | +10.0% | -15.8% | +12.1% | – | |
| – | +9.4% | +2.4% | +17.3% | -9.7% | +9.7% | -20.6% | +23.6% | -7.8% | +15.8% | -16.6% | +17.8% | – | |
| – | +8.2% | -19.5% | +60.3% | -9.5% | -14.8% | -7.2% | +5.3% | -7.8% | +2.9% | -18.0% | +28.6% | – | |
| – | +6.7% | +5.2% | +20.9% | -14.4% | +6.8% | -15.1% | +7.6% | -0.6% | +5.2% | -5.4% | +5.6% | – | |
| – | +11.4% | -2.0% | +61.9% | -33.8% | +5.8% | -19.2% | +7.2% | -1.6% | +6.2% | -5.8% | +7.1% | – | |
| – | -51.8% | +323.0% | -738.7% | – | +96.1% | -37.7% | +274.4% | -35.0% | +79.4% | -59.1% | +115.2% | – | |
| – | +1.6% | +0.6% | -4.0% | -4.0% | -5.6% | -16.5% | -0.2% | -17.6% | -14.1% | -18.5% | -6.0% | – | |
| – | – | – | – | – | – | -1,572.8% | – | -54.7% | +202.8% | -68.1% | +238.9% | – | |
| – | -225.0% | – | -909.2% | – | -6.6% | -117.3% | – | -36.2% | -578.2% | – | -3,759.7% | – | |
| – | – | – | – | – | – | – | – | -57.7% | +367.7% | -78.9% | +974.2% | – | |
| – | -9.0% | +16.1% | -211.4% | – | +27.4% | -26.2% | +87.1% | -25.5% | +40.0% | -35.6% | -3.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.